GoAI
Get started
Intuitive Surgical, Inc. logo

Intuitive Surgical, Inc.

ISRG

NASDAQHealthcareMedical - Instruments & Supplies

Open in GoAI

Previous close

$378.81

+$4.33 · +1.16%

Aug 21, 4:00 PM ET

Pre-market

$380.39

+$1.58 · +0.42%

Aug 24, 5:19 AM ET

ISRG company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

48

Fair Value

Momentum

36

Weakening

Sentiment

69

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
David J. Rosa
Listed since
Jun 16, 2000
Employees
17,021

Market position

Day range

Current $378.81

52-week range

Current $378.81

Open
$375.57
Previous close
$374.48
Volume
2.01M
0.69× average
Average volume
2.91M
Average daily volume
Market cap
133.83B USD
Beta
1.46
Market reference 1
50-day average
$388.3
-2.44% below average
200-day average
$473.15
-19.94% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
199.07B USD
P/E (TTM)
42.8×
P/B (TTM)
7.39×
P/S (TTM)
12.13×
EV / EBITDA
49.91×
Earnings yield
1.41%
Free cash flow yield
1.23%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
66.68%
Operating margin
31.28%
Net margin
28.45%
Return on equity
16.02%
Return on assets
13.84%
Return on invested capital
13.71%

Financial health

Debt / equity
0×
Current ratio
4.87×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends74%55%36%16%Gross margin, FY2021: 69.32%Gross margin, FY2022: 67.44%Gross margin, FY2023: 66.39%Gross margin, FY2024: 67.46%Gross margin, FY2025: 66.00%Operating margin, FY2021: 31.89%Operating margin, FY2022: 25.35%Operating margin, FY2023: 24.80%Operating margin, FY2024: 28.12%Operating margin, FY2025: 29.27%Net margin, FY2021: 29.85%Net margin, FY2022: 21.25%Net margin, FY2023: 25.24%Net margin, FY2024: 27.81%Net margin, FY2025: 28.38%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 69.32%. Gross margin FY2022 67.44%. Gross margin FY2023 66.39%. Gross margin FY2024 67.46%. Gross margin FY2025 66.00%. Operating margin FY2021 31.89%. Operating margin FY2022 25.35%. Operating margin FY2023 24.80%. Operating margin FY2024 28.12%. Operating margin FY2025 29.27%. Net margin FY2021 29.85%. Net margin FY2022 21.25%. Net margin FY2023 25.24%. Net margin FY2024 27.81%. Net margin FY2025 28.38%.

Income trends

Revenue

10.06B USD+20.51%

Operating income

2.95B USD+25.40%

Net income

2.86B USD+22.97%
Income trends across reported periods10.94B USD7.44B USD3.95B USD448.06M USDRevenue, FY2021: 5.71B USDRevenue, FY2022: 6.22B USDRevenue, FY2023: 7.12B USDRevenue, FY2024: 8.35B USDRevenue, FY2025: 10.06B USDOperating income, FY2021: 1.82B USDOperating income, FY2022: 1.58B USDOperating income, FY2023: 1.77B USDOperating income, FY2024: 2.35B USDOperating income, FY2025: 2.95B USDNet income, FY2021: 1.7B USDNet income, FY2022: 1.32B USDNet income, FY2023: 1.8B USDNet income, FY2024: 2.32B USDNet income, FY2025: 2.86B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.71B USD. Revenue FY2022 6.22B USD. Revenue FY2023 7.12B USD. Revenue FY2024 8.35B USD. Revenue FY2025 10.06B USD. Operating income FY2021 1.82B USD. Operating income FY2022 1.58B USD. Operating income FY2023 1.77B USD. Operating income FY2024 2.35B USD. Operating income FY2025 2.95B USD. Net income FY2021 1.7B USD. Net income FY2022 1.32B USD. Net income FY2023 1.8B USD. Net income FY2024 2.32B USD. Net income FY2025 2.86B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue10.06B USD8.35B USD7.12B USD6.22B USD5.71B USD
Cost of goods sold3.42B USD2.72B USD2.39B USD2.03B USD1.75B USD
Gross profit6.64B USD5.63B USD4.73B USD4.2B USD3.96B USD
Research and development1.31B USD1.15B USD998.8M USD879M USD671M USD
Selling, general, and administrative2.39B USD2.14B USD1.96B USD1.74B USD1.47B USD
Operating expenses3.7B USD3.29B USD2.96B USD2.62B USD2.14B USD
Interest income365.9M USD324.9M USD192.1M USD29.7M USD69.3M USD
Depreciation and amortization677.1M USD462M USD402.2M USD365.8M USD317M USD
Operating income2.95B USD2.35B USD1.77B USD1.58B USD1.82B USD
Net income2.86B USD2.32B USD1.8B USD1.32B USD1.7B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
100%
11 beats, 0 misses, 0 met estimates
Average EPS surprise
+12.96%
11 comparable reports
Latest EPS result
2.8
Estimate 2.48 · Beat by 12.90%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.912.482.061.63Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 23, 2025: actual 2.21, estimate 1.76, surprise +25.57%, Beat. Q2 2025, reported Apr 22, 2025: actual 1.81, estimate 1.74, surprise +4.02%, Beat. Q3 2025, reported Jul 22, 2025: actual 2.19, estimate 1.93, surprise +13.47%, Beat. Q4 2025, reported Oct 21, 2025: actual 2.4, estimate 1.99, surprise +20.60%, Beat. Q1 2026, reported Jan 22, 2026: actual 2.53, estimate 2.27, surprise +11.45%, Beat. Q2 2026, reported Apr 21, 2026: actual 2.8, estimate 2.51, surprise +11.55%, Beat. Q3 2026, reported Jul 16, 2026: actual 2.8, estimate 2.48, surprise +12.90%, Beat. Q4 2026, reported Oct 20, 2026: actual —, estimate 2.61, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.02B2.71B2.39B2.07BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 23, 2025: actual 2.41B USD, estimate 2.25B USD, surprise +7.32%, Beat. Q2 2025, reported Apr 22, 2025: actual 2.25B USD, estimate 2.19B USD, surprise +3.09%, Beat. Q3 2025, reported Jul 22, 2025: actual 2.44B USD, estimate 2.35B USD, surprise +3.77%, Beat. Q4 2025, reported Oct 21, 2025: actual 2.51B USD, estimate 2.41B USD, surprise +4.10%, Beat. Q1 2026, reported Jan 22, 2026: actual 2.87B USD, estimate 2.76B USD, surprise +3.75%, Beat. Q2 2026, reported Apr 21, 2026: actual 2.77B USD, estimate 2.62B USD, surprise +5.81%, Beat. Q3 2026, reported Jul 16, 2026: actual 2.89B USD, estimate 2.83B USD, surprise +2.37%, Beat. Q4 2026, reported Oct 20, 2026: actual —, estimate 2.91B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

57 ratings
Strong buy00%
Buy4070%
Hold1221%
Sell59%
Strong sell00%

ISRG peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

—

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

—

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

—

Sanofi logo

SNY

Sanofi

$45.85

—

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

—

argenx SE logo

ARGX

argenx SE

$1,039.78

—

ETFs holding ISRG

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.98B
Weight
0.17%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24—
Vanguard S&P 500 ETF logoVanguard S&P 500 ETFVOO
Market value
3.28B
Weight
0.19%
AUM
1.7T USD
Expense ratio
0.03%
Price / 1D
$703.71—
Invesco QQQ Trust, Series 1 logoInvesco QQQ Trust, Series 1QQQ
Market value
2.86B
Weight
0.59%
AUM
485.41B USD
Expense ratio
0.18%
Price / 1D
$713.44—
iShares Core S&P 500 ETF logoiShares Core S&P 500 ETFIVV
Market value
1.79B
Weight
0.20%
AUM
891.84B USD
Expense ratio
0.03%
Price / 1D
$769.31—
State Street SPDR S&P 500 ETF logoState Street SPDR S&P 500 ETFSPY
Market value
1.65B
Weight
0.20%
AUM
817.87B USD
Expense ratio
0.09%
Price / 1D
$765.72—
Vanguard Morningstar Growth ETF logoVanguard Morningstar Growth ETFVUG
Market value
1.35B
Weight
0.36%
AUM
372B USD
Expense ratio
0.03%
Price / 1D
$87.50—
State Street Health Care Select Sector SPDR ETF logoState Street Health Care Select Sector SPDR ETFXLV
Market value
954M
Weight
2.13%
AUM
—
Expense ratio
—
Price / 1D
$174.62—
Invesco NASDAQ 100 ETF logoInvesco NASDAQ 100 ETFQQQM
Market value
609.47M
Weight
0.59%
AUM
104.09B USD
Expense ratio
0.15%
Price / 1D
$293.76—

Continue in GoAI

Research ISRG

research.disclaimer